Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

@article{Moore2007ErlotinibPG,
  title={Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.},
  author={M. Moore and D. Goldstein and J. Hamm and A. Figer and J. Hecht and S. Gallinger and H. Au and P. Murawa and D. Walde and R. Wolff and D. Campos and R. Lim and K. Ding and G. Clark and T. Voskoglou-Nomikos and Mieke Ptasynski and W. Parulekar},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 15},
  pages={
          1960-6
        }
}
  • M. Moore, D. Goldstein, +14 authors W. Parulekar
  • Published 2007
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. PATIENTS AND METHODS… Expand

Paper Mentions

Observational Clinical Trial
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in… Expand
ConditionsCancer, Pancreatic Cancer
InterventionOther, Procedure
Interventional Clinical Trial
The primary purpose of this study is to assess whether Acelarin (NUC-1031) is superior to gemcitabine in terms of overall survival for treatment of patients with metastatic pancreatic… Expand
ConditionsPancreatic Acinar Carcinoma, Pancreatic Neoplasms
InterventionDrug
Interventional Clinical Trial
Background: - Stereotactic body radiation therapy (SBRT) is used to treat cancer. It is a way of giving very focused beams of radiation to tumors. Researchers think that the… Expand
ConditionsCancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer, (+2 more)
InterventionBiological, Radiation
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
  • M. Sinn, M. Bahra, +18 authors H. Riess
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
Optimal treatment of metastatic pancreatic cancer
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
...
1
2
3
4
5
...